Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

MicroRNA Profiles in Triple Negative Breast Cancer

Phase 2

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2021-02-25

Last Posted Date: 2022-02-18

Lead Sponsor: University College Hospital, Ibadan

Target Recruit Count: 42

Registration Number: NCT04771871

Locations: 🇳🇬
Lagos State University Teaching Hospital, Lagos, Nigeria
🇳🇬
Lagos University Teaching Hospital, Lagos, Nigeria
🇳🇬
Obafemi Awolowo University Teaching Hospital, Ile-Ife, Oshun, Nigeria

and more 1 locations

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Phase 1

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Niraparib
Drug: Paclitaxel
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Pegfilgrastim

First Posted Date: 2021-02-21

Last Posted Date: 2022-04-26

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT04762901

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Phase 3

Recruiting

Conditions: Primary Mediastinal Large B-Cell Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Procedure: Echocardiography
Drug: Etoposide Phosphate
Biological: Filgrastim
Procedure: Lumbar Puncture
Biological: Pegfilgrastim
Biological: Nivolumab
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy
Drug: Prednisolone
Drug: Prednisone
Biological: Rituximab
Biological: Rituximab and Hyaluronidase Human
Drug: Vincristine Sulfate

First Posted Date: 2021-02-18

Last Posted Date: 2025-01-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 244

Registration Number: NCT04759586

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 226 locations

Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients

Phase 3

Recruiting

Conditions: Advanced Soft-tissue Sarcoma
Metastatic Soft-tissue Sarcoma

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2021-02-17

Last Posted Date: 2024-06-17

Lead Sponsor: UNICANCER

Target Recruit Count: 214

Registration Number: NCT04757337

Locations: 🇫🇷
Institut Claudius Reagaud-IUCT Oncopôle, Toulouse, France

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Phase 1

Active, not recruiting

Conditions: AL Amyloidosis

Interventions: Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Dexamethasone
Biological: Isatuximab

First Posted Date: 2021-02-15

Last Posted Date: 2024-06-26

Lead Sponsor: Emory University

Target Recruit Count: 11

Registration Number: NCT04754945

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 3 locations

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Recurrent Chronic Myelomonocytic Leukemia
Hematopoietic and Lymphoid Cell Neoplasm
Recurrent Acute Myeloid Leukemia
Recurrent Acute Lymphoblastic Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Refractory Chronic Myelomonocytic Leukemia
Refractory Myelodysplastic Syndrome

Interventions: Drug: DS-1594b
Drug: Azacitidine
Drug: Cyclophosphamide
Drug: Posaconazole
Drug: Venetoclax
Drug: Cytarabine
Drug: Voriconazole
Drug: Dexamethasone
Biological: Filgrastim
Drug: Leucovorin
Drug: Mesna
Drug: Methotrexate
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine

First Posted Date: 2021-02-12

Last Posted Date: 2023-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17

Registration Number: NCT04752163

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Different Immunosuppressive Treatment in iMN

Phase 3

Recruiting

Conditions: Idiopathic Membranous Nephropathy

Interventions: Drug: Prednisone
Drug: Rituximab
Drug: Cyclophosphamide

First Posted Date: 2021-02-09

Last Posted Date: 2022-04-20

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 200

Registration Number: NCT04745728

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Phase 2

Recruiting

Conditions: Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma

Interventions: Drug: Brentuximab Vedotin
Drug: Cyclophosphamide
Drug: Doxorubicin
Biological: Nivolumab
Drug: Prednisone
Other: Quality-of-Life Assessment
Biological: Rituximab

First Posted Date: 2021-02-09

Last Posted Date: 2025-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT04745949

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase 1 Study of ADI-001 in B Cell Malignancies

Phase 1

Recruiting

Conditions: Lymphoma, Non-Hodgkin
Lymphoma, Mantle-Cell
Marginal Zone Lymphoma
Primary Mediastinal B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Lymphoma, Follicular

Interventions: Genetic: ADI-001
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-02-03

Last Posted Date: 2024-04-10

Lead Sponsor: Adicet Therapeutics

Target Recruit Count: 78

Registration Number: NCT04735471

Locations: 🇺🇸
Baylor Scott & White Research Institute, Dallas, Texas, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
University of Miami- Sylvester Comprehensive Cancer Center, Miami, Florida, United States

and more 7 locations

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Phase 1

Suspended

Conditions: Non Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia

Interventions: Biological: Fully human anti CD19 CAR-T Cell Dose
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-02-01

Last Posted Date: 2025-01-06

Lead Sponsor: Benjamin Tomlinson

Target Recruit Count: 36

Registration Number: NCT04732845

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy